Table 1.

Baseline characteristics of the trials included in the meta-analysis

Author	Treatment regimen	No. of patients	Median age (year, range)	Gender (F/M)	Duration (months)	outcomes	Jaded score
Black DM [20]	PTH (1-84) 100 μg daily+ alendronate 10 mg daily	59	70.2 ± 6.8	F	12	Areal BMD: lumbar spine, total hip, femoral neck, distal radius. Volumetric BMD: lumbar spine, total hip, femoral neck, distal radius. Markers of bone turner	4
	PTH (1-84) 100 μg daily	119	69.4 ± 7.3	F	12
Finkelstein JS [21]	Teriparatide 40 μg subcutaneously daily+ alendronate 10 mg orally once daily	25	58 ± 8	M	30	Areal BMD: Posteroanterior spine, Lateral spine, total hip, femoral neck, distal radius, total body.	3
	Teriparatide 40 μg sc daily	20	57 ± 9	M	30
Finkelstein JS [29]	Teriparatide 40 μg sc daily+ alendronate 10 mg daily	20	62 ± 7	F	30	Areal BMD: Posterior-anterior spine, total hip, femoral neck, distal radius. Bone turner markers.	3
	Teriparatide 40 μg sc daily	20	65 ± 7	F	30
Boonen S [30]	Teriparatide 20 μg/d and daily supplements of 500 mg elemental calcium and 400-800 IU vitamin D + alendronate	107	70.3	F	24	Areal BMD: total hip, femoral neck, lumbar spine.	4
	Teriparatide 20 μg/d and daily supplements of 500 mg elemental calcium and 400-800 IU vitaminD + non- bisphosphonate	49	67.9	F	24
Miller PD [31]	Teriparatide 20 μg/d+ alendronate 10 mg daily or 70 mg weekly	146	67.7 ± 7.8	F	12	Areal BMD: total hip, femoral neck. Volumetric BMD: lumbar spine, total hip. Bone turner markers.	3
	Teriparatide 20 μg/d	146	69.3 ± 7.4	F	12
Cosman F [32]	Teriparatide 20 μg/d and daily supplements of 500 mg elemental calcium and 400-800 IU vitamin D + alendronate	52	67.8 ± 1.4	F	18	Areal BMD: lumbar spine, total hip, femoral neck. Biochemical markers of bone metabolism.	3
	Teriparatide 20 μg/d and daily supplements of 500 mg elemental calcium and 400-800 IU vitamin D	50	69.1 ± 1.4	F	18